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Abstract
Background: Little is known about vitamin D status in low-income populations burdened with infectious diseases. Hence,
there is a need for data on correlates of serum 25-hydroxy vitamin D (S-25(OH)D) and its validity during infections.
Objective: To assess the role of pulmonary TB (PTB) and HIV as correlates of S-25(OH)D.
Design: Age-sex-matched cross-sectional study among PTB patients and non-TB controls.
Methods: PTB patients were categorized as sputum negative (PTB2) and positive (PTB+) by culture. Non-TB controls were
randomly selected among age-sex-matched neighbours to PTB+ patients. Height, weight, arm circumference and triceps
skinfold were measured, and body mass index (BMI), arm fat (AFA) and muscle area (AMA) computed. HIV status, and S-
25(OH)D, C-reactive protein (S-CRP) and a1-acid glycoprotein (S-AGP) were determined. Linear regression analysis with
controls and PTB patients combined was used to identify correlates of S-25(OH)D.
Results: S-25(OH)D data were available on 97.8% (1570) of 1605 participants. Mean (SD) S-25(OH)D was 84.4 (25.6) nmol/L
with 39.6% ,75 nmol/L among 347 non-TB controls. Time of recruitment, sex, PTB and HIV, and elevated S-AGP were
correlates of S-25(OH)D. S-25(OH)D was 24.8 (95% CI 18.6;30.9) nmol/L higher in PTB compared to controls among females,
but only 9.8 (95% CI:4.5;15.2) nmol/L among males (interaction p,0.0001). Females had 13.8 (95% CI:8.2;21.9) nmol/L lower
S-25(OH)D than males, and HIV infected individuals had 8.5 (95% CI:4.9;12.1) higher S-25(OH)D compared to uninfected.
Elevated S-AGP was a positive correlate of S-25(OH)D. Low BMI was associated with S-25(OH)D, but not with infections or S-
AGP in the model.
Conclusion: While S-25(OH)D may decline transiently during a mild acute phase response, it may increase if the acute phase
response leads to loss of fat. The validity of S-25(OH)D as a marker of vitamin D status may be affected by infections.
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Introduction
Although vitamin D is mainly synthesized in the skin during sun
exposure, hypovitaminosis D has been shown to be common in
low-income countries, including those in equatorial Africa [1–3].
Since vitamin D is an immunoregulatory hormone and a possible
determinant of infectious diseases [4], inadequate vitamin D status
may be a public health problem.
There is evidence to suggest that hypovitaminosis D increases
the risk of tuberculosis (TB) [5]. Vitamin D binds to nuclear
receptors in macrophages, leading to an oxidative burst which is
important for the intracellular antimycobacterial activity [6], and
vitamin D metabolites upregulate nitric oxide synthase which
serves to suppress mycobacterial growth [7]. Yet, the epidemio-
logical evidence is not convincing. No data from trials on the effect
of vitamin D on risk of TB disease have been reported [8], and the
results from case-control studies are inconsistent [3,5,9]. A
problem with case-control studies is that vitamin D status is
assessed when TB is diagnosed, at which time pathogenic disease
processes are already flourishing. Associations between low serum
concentrations of 25-hydroxy-cholecalciferol (serum 25(OH)D)
and TB reported from many case-control studies are interpreted as
reflecting that low vitamin D status increases the risk of TB.
Nevertheless, this association could be explained by reverse
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causality, if TB itself impairs vitamin D status or if the acute phase
response precipitated by TB impairs the validity of serum
25(OH)D as a marker of vitamin D status. Indeed, a couple of
studies have demonstrated that serum 25(OH)D decline following
during surgery [10,11].
We have previously reported hypovitaminosis D among 655
pulmonary TB (PTB) patients in Mwanza, Tanzania, which was
not explained by the acute phase response [1], but lack of
appropriate non-TB controls in that study was a limitation.
Therefore, as part of a larger nutrition study, we obtained cross-
sectional data on serum 25(OH)D among PTB patients and age-
sex-matched neighbourhood controls, with an aim to assess
vitamin D status and the role of PTB and HIV as correlates of
serum 25(OH)D.
Methodology
Ethics Statement
Ethical permission was obtained from the Medical Research
Coordinating committee of the National Institute for Medical
Research in Tanzania, and consultative approval was given by
The Danish Central Medical Ethics Committee. Written and oral
information was presented to all eligible participants by the health
staff before written informed consent was obtained. Written
consent was obtained from parents/legal guardians of any
participants under 18 years of age.
Study Setting and Design
A cross-sectional study conducted from April 2006 to March
2009 in Mwanza City, Tanzania, among PTB patients recruited
for a large nutrition intervention study and non-TB controls.
Mwanza City is at the shores of Lake Victoria, at latitude 2.28 S,
longitude 32.55 E, and an altitude of 1140 m. The annual rainfall
is 700–1000 mm, with long rains from February to April and short
rains in November and January. The mean number of daily
sunshine hours ranges from 7.0 to 9.0 per day, lowest in October
to April with 7.0–7.4 h/d and highest in June and July with 9.0 h/
d [1]. The population is generally unveiled, with faces and often
arms exposed to the sun. The harvest is from May to July, and the
staple foods are maize, cassava, sweet potato, rice, and millet. Fish
is the most common animal-source food.
Recruitment and Management of TB Patients
The PTB patients were recruited at the four TB clinics under
the TB treatment services, coordinated by the National Tubercu-
losis and Leprosy Programme. Smear-positive (PTB+) or –negative
(PTB2) patients were enrolled in the study after giving informed
consent if they were residents of Mwanza city, to allow follow-up.
Patients with extra-pulmonary TB, pregnancy, age under 15 years,
or terminal illness were excluded. The diagnosis of TB followed
the World Health Organization (WHO) guidelines [12] using the
Ziehl–Neelsen staining technique [13]. Briefly, all TB suspects
were asked to bring three sputum samples, ie spot-morning-spot
samples, for microscopy, and were asked to do a chest X-ray as
appropriate. Patients were considered to be smear-positive, if two
samples tested positive or one sample tested positive and a chest X-
ray was suggestive of TB, and to be smear-negative, if all the
samples were negative, but chest X-ray was suggestive of TB, and
there was non-response to a course of broad-spectrum antibiotics,
eg amoxicillin. After diagnosis all patients were started on a
standardized TB treatment for 6–8 months based on existing
national guidelines [14,15]. The management of HIV infection
was done based on national guidelines at the time of the study
[16]. Patients were supposed to start antiretroviral therapy (ART)
if they had CD4 count of ,200 cells/ml, those with WHO stage 4
illness and/or CD4 count of 200–350 cells/ml were supposed to
start ART after completion of two months of TB treatment.
Patients who developed TB after starting ART continued with
ART throughout TB treatment.
Recruitment of Non-TB Controls
Among PTB patients recruited for the nutrition intervention
trials (clinicaltrials.gov, NCT0031129) it was planned to designate
up to 400 consecutive smear-positive participants as index cases
for selection of age-sex-matched neighbourhood non-TB controls.
Mwanza City is divided into wards, streets and communal cells.
Each cell has 10–20 households, and is headed by a ten cell-leader.
Each of the index patients who were eventually recruited was
asked to provide his/her residential address and the name of his/
her ten-cell leader. Using this information, the study team
requested the ten-cell leader to provide the complete list of
individuals in his/her jurisdiction meeting the age and sex
recruitment criteria. Of these, one was randomly selected using
a lottery method and invited to participate in the study as a non-
TB control if meeting the following criteria: no history of previous
or TB exposure, active TB or TB treatment, no evidence of
current active TB (cough, intermittent fevers, and excessive night
sweating in the past two weeks and unexplained weight loss in the
past month), same sex as index case, aged 15 years or above and
age difference from index case was not more than five years, had
lived in the same street as index case for at least three months, not
pregnant, and consenting to participate in the study. Persons who
were terminally ill were not invited. If the selected individual
declined to participate, then another from the list was randomly
selected.
Data Collection
For the purpose of the study, all PTB patients provided an
additional sputum sample for culture at the Zonal TB Reference
Laboratory, and were subsequently categorized as sputum culture-
positive (PTB+) or culture-negative (PTB2). All PTB patients and
controls had data on demography, smoking, and alcohol intake
collected using questionnaires, while data on antiretroviral
treatment (ART) were retrieved from antiretroviral-use databases
in ART clinics. Weight, height, mid-upper arm circumference
(MUAC) and triceps skin fold thickness (TSFT) were determined.
From weight and height, body mass index (BMI) was calculated
using the formula: weight (kg)/(height (m))2. From MUAC and
TSFT, arm muscle area and arm fat area were calculated using
the formulae: arm muscle area = [MUAC2(TSFT6p)]2/(46p)
and arm fat area = [MUAC2/(46p)] – arm muscle area, as
measures of lean and fat mass [17]. Between 8 am and 12 noon, as
soon as possible and preferably before start of TB treatment, blood
was collected in a 10 ml plain vacutainer tube for HIV testing and
a 5 ml EDTA vacutainer tube for CD4 count. HIV status was
determined using Capillus HIV-1/HIV-2 (Trinity Biotech Plc.,
Wicklow, Ireland) and Determine HIV-1/HIV-2 (Inverness
Medical Innovations, Inc., Delaware, U.S.A.) tests in parallel
[18]. HIV infection was diagnosed if both tests gave a positive
result and HIV negative diagnosis was made if both tests produced
a negative result. Indeterminate results were resolved using
ELISA– Organon Uniform II (Organon Teknia Ltd, Boxtel,
Netherlands) [19]. CD4 count was determined as cells/ml using a
Partec Cyflow Counter (Partec GmbH, Mu¨nster, Germany). Serum
samples were kept frozen at 280uC at NIMR lab after collection
and were transported to Denmark on dry ice and kept at 280uC
until analysis, after a maximum of 3 years storage, of serum
25(OH)D were conducted at Aalborg Hospital, FBE Clinical
Vitamin D and TB
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Biochemistry South, using a fully automated direct competitive
chemiluminescent immunoassay (LIAISON 25-OH Vitamin D
TOTAL, DiaSorin Inc, Stillwater, Minnesota, USA) [20]. Within-
run and total precision were 2.9–5.5% and 6.3–12.9%, respec-
tively. Serum 25(OH)D ,50 nmol/L was used to define vitamin
D deficiency and ,75 nmol/L to define hypovitaminosis D [21].
To be able to adjust for the acute phase response, serum a1-acid
glycoprotein (AGP) was determined with a standard Alpha1-Acid
Glycoprotein Kit using Beckman Coulter ImageH Immunochem-
istry Systems (Beckman Coulter, Galway, Ireland) and C-reactive
protein (hsCRP) was determined with Tina-quant C-Reactive
Protein Gen.3 (CRPL3) on a Roche COBAS 6000 instrument
(Roche Diagnostics GmbH, Mannheim, Germany).
Statistical Analysis
Normal probability plots were used to assess the distribution of
continuous variables. Chi-square test was used to test for
differences in proportions. The two-sample t test or oneway
ANOVA were used to test for differences in means between two or
more groups, respectively. The analysis was done with controls
and PTB combined. Linear regression analysis was used to identify
correlates of serum 25(OH)D as a continuous variable, and to test
for interactions with PTB. The variables assessed were age, sex,
anthropometry, PTB and HIV status, and elevated serum CRP
(.2 mg/L) or AGP (.1.0 mg/L), with adjustment for season
through variables corresponding to quarter and year of recruit-
ment, with all variables initially in the model. Models are
presented with and without adjustment for elevated serum AGP
using dummy variables with values below 1.0 mg/L as reference
category. If interaction with PTB status was identified, then the
association was expressed separately for each. Normal and
residual-vs.-fitted plots were used to assess normality and
homoscedasticity of residuals. Stata version 11.0 (StataCorp,
Texas, USA) was used for all analyses.
Results
Of 1605 individuals included in the study, 1250 (77.9%) were
PTB patients and 355 (22.1%) controls. Of the PTB patients, 427
(34.2%) were PTB2 and 823 (65.8%) PTB+. HIV prevalence was
higher among PTB patients compared to controls (50.4 vs 9.9%,
p,0.001), and higher among PTB2 compared to PTB+ patients
(64.4 vs 43.1%, p,0.001). Of 636 HIV infected, 79 (12.2%) were
on ART. Data on serum 25(OH)D were available on 1569 (97.8%)
of the 1605 participants.
Among 347 non-TB controls, mean (SD) serum 25(OH)D was
84.4 (25.6) nmol/L, with 39.6% (137) having hypovitaminosis D
(,75 nmol/L), including 4.3% (15) with vitamin D deficiency
(,50 nmol/L). Serum 25(OH)D was 26.4 (95% CI: 22.4; 30.5)
nmol/L higher among the 1223 PTB patients, with mean (SD) of
110.9 (35.7) nmol/L, and 15.0% (184) had hypovitaminosis D,
including 2.5% (31) with vitamin D deficiency. Among PTB
patients, the mean (range) delay of blood sampling for serum
25(OH)D determination was 2.0 (0–14) days after initiation of TB
treatment. Mean serum 25(OH)D declined with time after
treatment start, as it was 113.1 nmol/L among the 540 (44.9%)
examined at the day of treatment, and 110.0 nmol/L among the
521 (43.3%) examined within 1–5 days and 104.8 nmol/L among
the 143 (5.7%) examined within 6–14 days (p = 0.04, linear trend
p = 0.01). The PTB patients were recruited from April 2006 to
November 2008, and controls from October 2006 to January
2009. For both groups, serum 25(OH)D varied considerably
between and within years (Figure 1). Among PTB patients, levels
were higher in 2006 and 2007 compared to 2008, and in the first
or second quarter. A less distinct pattern was seen for controls,
recruited with up to two months delay.
Serum 25(OH)D by sex, age, BMI, TB and HIV and ART
status, and elevated serum acute phase reactants are shown in
Table 1, for TB patients and controls combined. As seen, low
BMI was associated with higher serum 25(OH)D. Similar patterns
were seen for AMA and AFA (data not shown). There was no
difference in serum 25(OH)D between PTB2 and PTB+ patients
(111.8 vs 110.4 nmol/L, p = 0.53), but PTB patients together had
26.4 (95% CI: 22.4; 30.5) nmol/L higher serum 25(OH)D than
controls. The difference by TB status was also determined among
the 345 pairs of PTB+ index cases and controls only, and serum
25(OH)D was found to be 21.8 (95% CI: 17.2; 26.4) nmol/L
higher in the PTB+ patients (data not shown). Similarly, ART-
Figure 1. Mean serum 25(OH)D among 355 neighbourhood controls (NHc) and 1250 pulmonary tuberculosis (PTB) patients at the
year and quarter (Q) of examination. Two cases from first quarter of 2006 and seven from 2009 not shown.
doi:10.1371/journal.pone.0081142.g001
Vitamin D and TB
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naı¨ve HIV infected had higher serum 25(OH)D than HIV
uninfected, while HIV infected on ART was in between. Elevated
serum CRP or AGP were also positively associated with serum
25(OH)D.
The roles of sex, age, anthropometry, PTB and HIV and ART
status, and elevated acute phase reactants as correlates of serum
25(OH)D, and interaction by TB, were assessed by multivariable
analysis, with adjustment for year and quarter. Since there was no
difference between PTB2 and PTB+, these groups were
combined as PTB. Without elevated serum acute phase reactants
in the model (Table 2, model 1), sex, PTB and HIV and ART
status were correlates of serum 25(OH)D, while age, BMI, AMA
and AFA were not. However, there was a strong interaction
between PTB and sex (P,0.0001), since PTB was associated with
24.8 (95% CI: 18.6; 30.9) nmol/L higher serum 25(OH)D
compared to controls among females, and 9.8 (95% CI: 4.5;
15.2) nmol/L among males. With PTB accounted for in the model
separately for females and males, females had 13.8 (95% CI: 8.2;
21.9) nmol/L lower serum 25(OH)D. ART-naı¨ve HIV infected
had 9.6 (95% CI: 4.5; 15.2) higher serum 25(OH)D compared to
uninfected, whereas there was no difference between HIV infected
on ART and HIV uninfected. The association between HIV and
serum 25(OH)D was not different between controls and PTB
(interaction p = 0.62). Elevated serum AGP was a strong positive
correlate of serum 25(OH)D (Table 2, model 2), while elevated
serum CRP was not. Adjustment for elevated serum AGP reduced
the strength of association of serum 25(OH)D with PTB, but not
HIV.
While none of the anthropometric variables were associated
with serum 25(OH)D with infections or serum AGP in the model,
the role of these variables were assessed separately. Interestingly,
interactions with respect to serum 25(OH)D were found between
PTB and both AFA (p = 0.03) and BMI (p = 0.051), but not AMA
(p = 0.47), due to negative associations among controls, but not
PTB patients. For example, the regression coefficient was 21.2
(95% CI: 22.0; 20.3) for BMI among controls, but 20.1 (95%
CI: 20.7; 0.5) among PTB patients.
Discussion
We found that PTB patients had considerably higher serum
25(OH)D than non-TB controls, contrary to what has been
reported from a number of other studies. A systematic review of
studies published from 1980–2006 with data on serum 25(OH)D
on PTB patients and controls was recently conducted [5]. Of seven
case-control studies identified with a total of 531 participants, five
studies reported lower serum 25(OH)D in cases compared to
controls, while two studies did not. For all studies combined,
serum 25(OH)D was 0.68 SD lower among cases. However, the
sample sizes were small, ranging between 30–145 participants.
Some studies did not use culture for diagnosing TB, some included
extra-pulmonary TB, and selection of controls was not optimal.
More recently, a study from Guinea-Bissau reported lower mean
serum 25(OH)D in PTB patients compared to unmatched healthy
controls, but a higher proportion of severe vitamin D deficiency
(,25 nmol/L) in the controls [3]. A study from Greenland found
a U-shaped relationship between serum 25(OH)D and PTB, in
that both levels below 75 and above 140 nmol/L were associated
with PTB [9].
Thus, the findings from case-control studies are inconsistent,
which may be due to selection bias. It may also reflect limitations
of the case-control design to assess the role of vitamin D status as a
risk factor for TB. For example, data on vitamin D status are
usually collected after TB disease has been diagnosed. It is
therefore not possible to draw any inferences about the direction of
a potential cause-effect relationship. TB disease itself may lead to
changes in sun exposure and dietary and supplemental vitamin D
intake, and such changes may be setting-specific. TB disease and
treatment may also have direct biological effects on the
metabolism of vitamin D. E.g., isoniazid and rifampicin has been
reported to reduce serum 25(OH)D [22], so if vitamin D status is
Table 1. Serum 25(OH)D in 1250 pulmonary TB patients and
355 neighbourhood controls by categories of sex, age, body
mass index, pulmonary TB and HIV status and elevated acute
phase reactants1.
% (n) Mean 95% CI P
Sex 0.18
Females 41.9 (657) 103.6 100.9; 106.3
Males 58.1 (912) 106.0 104.7; 108.8
Age (y) ,0.001
,25 22.2 (349) 99.0 95.5; 102.5
25–35 33.6 (527) 106.3 103.4; 109.2
35–45 24.0 (377) 107.4 103.5; 111.4
45–55 12.2 (192) 110.5 105.3; 115.6
55+ 7.9 (124) 101.0 95.3; 106.8
Pulmonary TB status1 ,0.001
Non-TB control 22.1 (346) 84.4 81.7; 87.1
PTB2 26.4 (414) 111.8 108.2; 115.4
PTB+ 51.6 (809) 110.4 108.0; 112.8
HIV and ART status ,0.001
HIV2 58.8 (923) 98.4 96.2; 100.6
HIV+/ART-naı¨ve 36.1 (567) 115.6 112.7; 118.5
HIV+/on ART 5.0 (79) 107.6 100.2; 114.3
Body mass index
percentile2
,0.0001
,25 41.7 (653) 108.7 106.4; 111.0
25–50 51.5 (806) 103.4 99.1; 107.6
50+ 6.8 (107) 95.9 92.6; 99.2
Serum C-reactive
protein
(mg/L)
,0.001
#2 19.2 (300) 87.7 84.1; 91.4
2–5 7.4 (115) 98.6 93.3; 103.8
5–10 5.9 (92) 105.4 96.9; 113.9
10–50 18.5 (289) 109.5 105.2; 113.7
50+ 49.1 (767) 110.8 108.4; 113.2
Serum a1-acid
glycoprotein
(mg/L)
,0.001
#1 25.0 (391) 86.8 84.0; 89.7
1–2 20.2 (317) 109.1 105.0; 113.2
2–3 38.1 (596) 111.1 108.4; 113.9
3+ 16.8 (263) 113.1 108.8; 117.4
1Pulmonary TB status was based on culture, except where culture data were not
available. For 355 consecutively recruited sputum positive TB patients a control
was randomly selected among individuals with same sex and age from the
neighbourhood. Serum 25(OH)D data were available on 1570, but n may sum
up to less, due to missing data.
2Based on sex-specific percentiles among the neighbourhood controls.
doi:10.1371/journal.pone.0081142.t001
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assessed after commencement of TB treatment, which is usually
inevitable, this will create or contribute to an association between
low serum 25(OH)D and TB. The acute phase response
accompanying TB disease may also affect serum 25(OH)D
independently of vitamin D status per se, and as such impair the
validity of serum 25(OH)D as a marker of vitamin D status. This is
likely, since 25(OH)D is bound to vitamin D binding protein
(VDBP) and albumin in the blood, and many transport proteins,
and indeed albumin, are negative acute phase reactants, ie
declines during the acute phase response. Since several studies
have not been able to demonstrate such an effect of the acute
phase response, serum 25(OH)D has been considered to be a valid
measure of vitamin D status, even during infections. For example,
there was no evidence of a decline in a study among 14 children
followed during a malaria attack leading to hospitalization [23].
Similarly, in our previous study among PTB patients in Mwanza,
we failed to find any association between elevated serum levels of
the acute phase reactant a1-antichymotrypsin and serum
25(OH)D [1]. However, two prospective studies among patients
undergoing surgery found that serum 25(OH)D declined [10,11].
The decline in serum 25(OH)D may not only be explained by the
decline in serum concentrations of the transport protein, but could
also be due to increased uptake by macrophages [24]. The partly
transient decline in serum 25(OH)D seen in these studies may
explain the previously found negative associations between serum
25(OH)D and TB.
However, we found that elevated serum AGP was associated
with considerably higher serum 25(OH)D, and that this partially
explained the higher serum 25(OH)D in PTB patients. AGP is a
relatively slow reacting acute phase protein, so that high serum
AGP reflects more long-lasting disease. In contrast, we found no
association between serum CRP, a fast reacting acute phase
protein, and serum 25(OH)D in a multivariable model. This is
accordance with our previous finding of no association between
serum a1-antichymotrypsin (ACT), another relatively fast-reacting
acute phase protein, and serum 25(OH)D [1]. Interestingly, based
on a study in infants, associations between serum AGP and other
markers of inflammation, and levels of vitamin D binding protein
have previously been reported [25]. Our observation that serum
25(OH)D was lower with delayed blood sampling is likely to reflect
a rapid decline after start of TB treatment. Hence, since the acute
phase response per se seem to reduce rather than increase serum
25(OH)D (), then this is not explained by the fast decline in acute
phase reactants The decline is probably too rapid to be explained
by sequestration of vitamin D in newly deposited fat tissue [26]
and may instead be due to the effect of isoniazid and rifampicin as
previously reported [22].
As for the relationship between serum 25(OH)D and PTB, the
strength of our study is the random selection of age-sex-matched
non-TB neighbourhood controls and the size of the study. There
are several possible explanations for our finding of a higher serum
25(OH)D among PTB patients. First, greater sun exposure among
PTB patients during diagnosis and treatment of PTB cannot be
ruled out, whereas higher dietary or supplementary intake in
response to PTB diagnosis seems unlikely in this population.
Second, it could be due to reverse causality, ie that high vitamin D
status is a risk factor for PTB, as recently hypothesised [9]. High
vitamin D status has generally been associated with beneficial
health effects, but several studies now suggest that high vitamin D
status is associated with risk of disease or even all-cause mortality
[27]. Third, and most plausible, vitamin D may be released from
fat tissue lost during TB disease. Vitamin D is known to be
sequestered in fat tissue, which explains the negative association
between BMI and serum 25(OH)D found in studies among
Table 2. Correlates of serum 25(OH)D in 1250 pulmonary TB patients and 355 neighbourhood with regression coefficient B, 95%
confidence interval (CI) and P-values1.
Model 12 Model 23
B 95% CI P B 95% CI P
Sex
Female 213.8 221.9; 28.2 ,0.0001 213.6 220.4; 26.9 ,0.0001
Male – –
PTB status1
PTB among females 24.8 18.6; 30.9 ,0.0001 16.4 8.8; 24.0 ,0.0001
PTB among males 9.8 4.5; 15.2 ,0.0001 20.7 28.0; 6.6 0.83
Non-TB control –
HIV status
HIV+/ART-naı¨ve 9.6 6.0; 13.2 ,0.0001 8.9 5.2; 12.5 ,0.0001
HIV+/on ART 1.0 26.6; 8.6 0.80
HIV2 – –
Serum a1-acid glycoprotein (mg/L)
,1 –
1–2 11.8 5.5; 18.1 ,0.0001
2–3 11.6 5.2; 18.0 ,0.0001
3+ 12.7 5.7; 19.7 ,0.0001
1Pulmonary TB status was based on culture, except where culture data were not available. For 355 consecutively recruited sputum positive TB patients a control was
randomly selected among individuals with same sex and age from the neighbourhood. Age, and quarter and year of recruitment were adjusted for in both models.
2Model 1: N = 1540, adjusted R2 = 0.206 and intercept = 112.1 (95% CI: 105.1; 119.2).
3Model 2: N = 1537, adjusted R2 = 0.212 and intercept = 110.4 (95% CI: 103.3; 117.5).
doi:10.1371/journal.pone.0081142.t002
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healthy individuals [26,28,29]. Indeed, several studies have
reported considerable increments in serum 25(OH)D after
surgically induced weight loss (26–28).
So, it is likely that while a mild acute phase response leads to a
transient decline in serum 25(OH)D [10,11], a more severe and
sustained response leading to loss of fat mass results in an increase
in serum 25(OH)D, although metabolism of 25(OH)D may also be
affected. Two observations from our study seem to support this
interpretation. We found, in accordance with other studies [26], a
negative relationship between both BMI and AFA, but not AMA,
and serum 25(OH)D among controls. Interestingly, this expected
negative relationship was not seen among our PTB patients,
neither in this nor in our previous study. This may suggest that the
usual relation between serum 25(OH)D and measures of fat is
disturbed in PTB patients, possibly due to release of vitamin D
from fat tissue accompanied by changes in the metabolism of
vitamin D and binding proteins. We also found a strong
interaction between PTB and sex, as females had considerably
lower serum 25(OH)D than males among controls, whereas there
was no sex difference among PTB patients. It is known that
females lose relatively more fat than males during PTB as well as
HIV [30–33], and gain more during treatment (Praygod,
submitted). So, the lack of sex difference among PTB patients
could be due to greater loss of fat among females compared to
males, hence a greater release of vitamin D.
We also found that HIV was associated with higher serum
25(OH)D, and this was seen both among PTB patients and non-
TB controls. In contrast to PTB, the association with HIV was not
explained by the acute phase response, as HIV infection per se
does not lead to an acute phase response [34], or even impair the
response to other stimuli [35].
Year-to-year and Seasonal Variation
The seasonal variation, with highest serum 25(OH)D in the first
half of the year, was in accordance with our study among PTB
patients in 2001–2 [1]. In addition, this current study strongly
suggests considerable year-to-year variation in vitamin D status.
Not only was the mean serum 25(OH)D in the current study much
higher compared to the previous study (111 vs 86.7 nmol/L), but
in the current study serum 25(OH)D levels were higher in 2006–7
compared to 2008. The two studies were conducted in similar
study populations of newly diagnosed pulmonary PTB patients,
and the serum 25(OH)D analyses were done with similar
analytical equipment at the same laboratory. Although our
current data suggest that serum 25(OH)D increases during the
acute phase response, the variation is not explained by changes in
infectious disease burden, since we controlled for elevated serum
AGP. We therefore believe that both seasonal and year-to-year
variations reflect true variation in vitamin D status over time, due
to variation in sun exposure and dietary intake of vitamin D.
Conclusion
We found that PTB and HIV were associated with higher serum
25(OH)D. Elevated serum AGP was also a strong positive
correlate of serum 25(OH)D, and explained of the association
with PTB. We suggest that while S-25(OH)D may decline
transiently during a mild acute phase response, it may increase if
the acute phase response is severe and sustained and leads to loss
of fat. Differences in treatment lag time, and hence magnitude of
fat loss, may explain some of the inconsistencies between studies.
The validity of S-25(OH)D as a marker of vitamin D status may be
affected by infections. There is a need for prospective studies to
assess the relationship between vitamin D and risk of TB, HIV and
other infectious diseases.
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